Form 8-K - Current report:
SEC Accession No. 0001140361-24-046015
Filing Date
2024-11-12
Accepted
2024-11-12 07:22:27
Documents
14
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20038392_8k.htm   iXBRL 8-K 34576
2 EXHIBIT 99.1 ef20038392_ex99-1.htm EX-99.1 313013
  Complete submission text file 0001140361-24-046015.txt   505486

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20241112.xsd EX-101.SCH 3979
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20241112_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20241112_pre.xml EX-101.PRE 16042
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20038392_8k_htm.xml XML 4218
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 241443271
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)